dr. garcia on research with the combination of navitoclax/ruxolitinib in myelofibrosis
Published 4 years ago • 139 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
1:07
dr. garcia on the tolerability of navitoclax/ruxolitinib in myelofibrosis
-
1:07
dr. garcia on the role of navitoclax in myelofibrosis
-
1:01
dr. garcia on efficacy of navitoclax in ruxolitinib-resistant myelofibrosis
-
1:21
dr. garcia on managing thrombocytopenia with navitoclax in myelofibrosis
-
4:21
jacqueline garcia: evaluating navitoclax for myelofibrosis
-
1:50
dr. garcia on unmet need in myelofibrosis
-
8:17
can navitoclax plus ruxolitinib induce clinically relevant responses in patients with myelofibrosis?
-
4:11
why does adding navitoclax to ruxolitinib induce responses in patients with r/r mf?
-
4:58
treatment of myelofibrosis: emerging therapies
-
1:00
dr. kremyanskaya on effect of cpi-0610 in patients with myelofibrosis
-
1:08
dr. kremyanskaya on responses with cpi-0610 in patients with myelofibrosis
-
1:13
dr. mesa on new trials and agents in the pipeline in myelofibrosis
-
1:24
dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
-
1:42
dr. mesa on ruxolitinib vs fedratinib in myelofibrosis treatment
-
3:06
other pathways studied for mf
-
2:10
dr. verstovsek on accelerated phase myelofibrosis
-
2:03
dr. mesa on jakarta-2 reanalysis for myelofibrosis
-
2:18
dr. snyder on the quest to revolutionize management of myelofibrosis
-
1:12
dr. mesa on the differences between fedratinib and ruxolitinib in myelofibrosis